首页 > 最新文献

Reumatologia最新文献

英文 中文
Retrospective analysis of IgG4-related disease cases at a tertiary care centre in India 印度某三级保健中心igg4相关疾病病例的回顾性分析
Q3 RHEUMATOLOGY Pub Date : 2022-02-10 DOI: 10.5114/reum.2022.113517
M. Bhatt, Sanchit Kumar, M. Soneja, S. Vyas, M. Tripathi, R. Kumar, Prabhjot Singh, M. Sharma, N. Wig
Objectives IgG4-related disease (IgG4-RD) is a chronic inflammatory disorder with prominent fibrosis. This retrospective analysis was undertaken to study the clinical, laboratory, and radiological characteristics of patients with extra-pancreatic IgG4-RD and their response to treatment at a tertiary care centre located in northern India. Material and methods Patient data from our centre between January 2017 and January 2021 were reviewed. Probable/definite IgG4-RD cases were included in the analysis. Results A total of 14 cases were identified with a median age of 39 years (range 19–56 years). There were 10 males and 4 females. All patients presented with slowly progressive soft tissue swellings with pain/discomfort related to local mass effect. The median delay in diagnosis was 9.5 months (range 2–72 months). Cross-sectional imaging showed soft tissue masses in all cases. All contrast-enhanced studies (n = 7) showed enhancement on computed tomography and magnetic resonance imaging scan. F-18 fluorodeoxyglucose-avidity was observed in 8 of 9 (88.9%) cases. Biopsies performed in 12 of these were classified as definite in 8 and possible IgG4-RD in 4 cases. Patients were treated with a median dose of 1 mg/kg/day (range 0.5–1 mg/kg/day) prednisolone. Steroids were successfully tapered in all 12 cases with 41.6% (5 of 12) being off corticosteroids at a median follow-up of 10 months (range 0–18 months). Two patients were lost to follow-up. Conclusions IgG4-related disease is a chronic illness with a wide spectrum of manifestations, in which the diagnosis is often delayed, but it shows an excellent response to treatment. Efforts must be made to increase awareness among physicians about this disease to institute appropriate treatment as early as possible.
igg4相关疾病(IgG4-RD)是一种以纤维化为主的慢性炎症性疾病。本回顾性分析研究了位于印度北部三级保健中心的胰腺外IgG4-RD患者的临床、实验室和放射学特征及其对治疗的反应。材料和方法回顾了本中心2017年1月至2021年1月的患者数据。可能/确诊的IgG4-RD病例被纳入分析。结果14例患者中位年龄39岁(19 ~ 56岁)。其中男性10人,女性4人。所有患者均表现为缓慢进行性软组织肿胀,伴有与局部肿块效应相关的疼痛/不适。中位诊断延迟为9.5个月(范围2-72个月)。横断成像均显示软组织肿块。所有对比增强研究(n = 7)显示计算机断层扫描和磁共振成像扫描增强。9例患者中有8例(88.9%)出现F-18氟脱氧葡萄糖贪食。其中12例活检确诊8例,4例可能为IgG4-RD。患者接受中位剂量1mg /kg/天(范围0.5-1 mg/kg/天)强的松龙治疗。12例患者中有41.6%(5 / 12)的患者在中位随访10个月(范围0-18个月)后停止使用皮质类固醇。2例患者未随访。结论igg4相关性疾病是一种表现广泛的慢性疾病,诊断常被延误,但治疗反应良好。必须努力提高医生对这种疾病的认识,以便尽早制定适当的治疗办法。
{"title":"Retrospective analysis of IgG4-related disease cases at a tertiary care centre in India","authors":"M. Bhatt, Sanchit Kumar, M. Soneja, S. Vyas, M. Tripathi, R. Kumar, Prabhjot Singh, M. Sharma, N. Wig","doi":"10.5114/reum.2022.113517","DOIUrl":"https://doi.org/10.5114/reum.2022.113517","url":null,"abstract":"Objectives IgG4-related disease (IgG4-RD) is a chronic inflammatory disorder with prominent fibrosis. This retrospective analysis was undertaken to study the clinical, laboratory, and radiological characteristics of patients with extra-pancreatic IgG4-RD and their response to treatment at a tertiary care centre located in northern India. Material and methods Patient data from our centre between January 2017 and January 2021 were reviewed. Probable/definite IgG4-RD cases were included in the analysis. Results A total of 14 cases were identified with a median age of 39 years (range 19–56 years). There were 10 males and 4 females. All patients presented with slowly progressive soft tissue swellings with pain/discomfort related to local mass effect. The median delay in diagnosis was 9.5 months (range 2–72 months). Cross-sectional imaging showed soft tissue masses in all cases. All contrast-enhanced studies (n = 7) showed enhancement on computed tomography and magnetic resonance imaging scan. F-18 fluorodeoxyglucose-avidity was observed in 8 of 9 (88.9%) cases. Biopsies performed in 12 of these were classified as definite in 8 and possible IgG4-RD in 4 cases. Patients were treated with a median dose of 1 mg/kg/day (range 0.5–1 mg/kg/day) prednisolone. Steroids were successfully tapered in all 12 cases with 41.6% (5 of 12) being off corticosteroids at a median follow-up of 10 months (range 0–18 months). Two patients were lost to follow-up. Conclusions IgG4-related disease is a chronic illness with a wide spectrum of manifestations, in which the diagnosis is often delayed, but it shows an excellent response to treatment. Efforts must be made to increase awareness among physicians about this disease to institute appropriate treatment as early as possible.","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"43 1","pages":"4 - 11"},"PeriodicalIF":0.0,"publicationDate":"2022-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88532586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term administration of immunoglobulin in a patient with anti-SRP immune-mediated necrotizing myopathy. 抗srp免疫介导的坏死性肌病患者的长期免疫球蛋白管理。
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 DOI: 10.5114/reum.2022.123675
Filipe Oliveira Pinheiro, Pedro Madureira, Maria Seabra Rato, Lúcia Costa
in quadriceps
{"title":"Long-term administration of immunoglobulin in a patient with anti-SRP immune-mediated necrotizing myopathy.","authors":"Filipe Oliveira Pinheiro, Pedro Madureira, Maria Seabra Rato, Lúcia Costa","doi":"10.5114/reum.2022.123675","DOIUrl":"https://doi.org/10.5114/reum.2022.123675","url":null,"abstract":"in quadriceps","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 6","pages":"446-447"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/47/RU-60-154876.PMC9847102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9146022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Epidemiology of rheumatic and musculoskeletal diseases in a Nigerian peri-urban community: results of a cross-sectional survey using the COPCORD stage 1 model. 尼日利亚城郊社区风湿病和肌肉骨骼疾病的流行病学:使用COPCORD第一阶段模型的横断面调查结果
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 DOI: 10.5114/reum.2022.123667
Adelowo Olufemi, Olaosebikan Babatunde Hakeem, Wright Kikelomo Olalade, Ogundele O Sunday, Adedeji O Oluwole

Introduction: There is relative neglect of rheumatic and musculoskeletal diseases (RMDs) in sub-Saharan Africa (SSA). While hospital-based reports on RMDs abound, there is a paucity of population-based reports on these conditions which are otherwise recognized to cause functional disability and reduced quality of life in the affected individuals. Thus, the objective of this study is to determine the prevalence, diagnostic types, and predictors of musculoskeletal (MSK) pain in Agbowa, a peri-urban community in Lagos, South-West Nigeria.

Material and methods: This community-based survey utilized the World Health Organisation/International League of Association of Rheumatology Community Oriented Programme for the Control of Rheumatic Diseases (WHO/ILAR COPCORD) stage 1 model. All respondents had their profiles documented via modified COPCORD questionnaires. Pain intensity and functional disability were assessed by the Numerical Rating Scale (NRS) and Health Assessment Questionnaires Disability Index (HAQ-DI) respectively. The rheumatic and musculoskeletal diseases were classified using relevant validated criteria. Data obtained were analysed using SPSS Version 21.

Results: There were 3056 respondents who were predominantly female (59.2%). The period prevalence of MSK pain among the 3056 respondents was 58% (n = 1,773). There were significantly more females with MSK pain than males (62.8% vs. 37.2%, p = 0.001). Overall, 380 (12.4%) subjects had clinically diagnosed RMDs. The common RMDs in decreasing order were osteoarthritis (n = 185, 6.1%), chronic low back pain (n = 95, 3.1%) and soft tissue rheumatism (n = 52, 1.7%). The bivariate analysis showed that female sex, family history of MSK conditions, history of previous trauma, and some comorbidities were significantly associated with MSK pain. The median HAQ-DI was 0.6 (IQR 0.1-1.8) with significant disability (HAQ-DI ≥ 1) in 39.5% of the subjects.

Conclusions: The burden and impacts of these conditions are considerable. Thus, the government needs to devise programmes and policies to limit the effects of RMDs in such communities.

在撒哈拉以南非洲(SSA),风湿病和肌肉骨骼疾病(RMDs)相对被忽视。虽然以医院为基础的关于rmd的报告很多,但以人口为基础的关于这些疾病的报告很少,否则这些疾病被认为会导致受影响个人的功能残疾和生活质量下降。因此,本研究的目的是确定尼日利亚西南部拉各斯郊区Agbowa地区肌肉骨骼(MSK)疼痛的患病率、诊断类型和预测因素。材料和方法:这项以社区为基础的调查采用了世界卫生组织/国际风湿病协会联盟以社区为导向的风湿病控制计划(WHO/ILAR COPCORD)第一阶段模型。所有受访者都通过修改后的COPCORD问卷记录了他们的个人资料。分别采用数值评定量表(NRS)和健康评估问卷(HAQ-DI)评估疼痛强度和功能障碍。风湿病和肌肉骨骼疾病采用相关的验证标准进行分类。获得的数据使用SPSS Version 21进行分析。结果:调查对象3056人,以女性为主,占59.2%。3056名受访者中MSK疼痛的期间患病率为58% (n = 1,773)。MSK疼痛的女性明显多于男性(62.8%比37.2%,p = 0.001)。总体而言,380名(12.4%)受试者被临床诊断为rmd。常见的rmd依次为骨关节炎(185例,6.1%)、慢性腰痛(95例,3.1%)和软组织风湿病(52例,1.7%)。双变量分析显示,女性、MSK家族史、既往创伤史和一些合并症与MSK疼痛显著相关。中位HAQ-DI为0.6 (IQR为0.1 ~ 1.8),39.5%的受试者存在显著残疾(HAQ-DI≥1)。结论:这些疾病的负担和影响是相当大的。因此,政府需要制定计划和政策来限制rmd对这些社区的影响。
{"title":"Epidemiology of rheumatic and musculoskeletal diseases in a Nigerian peri-urban community: results of a cross-sectional survey using the COPCORD stage 1 model.","authors":"Adelowo Olufemi,&nbsp;Olaosebikan Babatunde Hakeem,&nbsp;Wright Kikelomo Olalade,&nbsp;Ogundele O Sunday,&nbsp;Adedeji O Oluwole","doi":"10.5114/reum.2022.123667","DOIUrl":"https://doi.org/10.5114/reum.2022.123667","url":null,"abstract":"<p><strong>Introduction: </strong>There is relative neglect of rheumatic and musculoskeletal diseases (RMDs) in sub-Saharan Africa (SSA). While hospital-based reports on RMDs abound, there is a paucity of population-based reports on these conditions which are otherwise recognized to cause functional disability and reduced quality of life in the affected individuals. Thus, the objective of this study is to determine the prevalence, diagnostic types, and predictors of musculoskeletal (MSK) pain in Agbowa, a peri-urban community in Lagos, South-West Nigeria.</p><p><strong>Material and methods: </strong>This community-based survey utilized the World Health Organisation/International League of Association of Rheumatology Community Oriented Programme for the Control of Rheumatic Diseases (WHO/ILAR COPCORD) stage 1 model. All respondents had their profiles documented via modified COPCORD questionnaires. Pain intensity and functional disability were assessed by the Numerical Rating Scale (NRS) and Health Assessment Questionnaires Disability Index (HAQ-DI) respectively. The rheumatic and musculoskeletal diseases were classified using relevant validated criteria. Data obtained were analysed using SPSS Version 21.</p><p><strong>Results: </strong>There were 3056 respondents who were predominantly female (59.2%). The period prevalence of MSK pain among the 3056 respondents was 58% (<i>n</i> = 1,773). There were significantly more females with MSK pain than males (62.8% vs. 37.2%, <i>p</i> = 0.001). Overall, 380 (12.4%) subjects had clinically diagnosed RMDs. The common RMDs in decreasing order were osteoarthritis (<i>n</i> = 185, 6.1%), chronic low back pain (<i>n</i> = 95, 3.1%) and soft tissue rheumatism (<i>n</i> = 52, 1.7%). The bivariate analysis showed that female sex, family history of MSK conditions, history of previous trauma, and some comorbidities were significantly associated with MSK pain. The median HAQ-DI was 0.6 (IQR 0.1-1.8) with significant disability (HAQ-DI ≥ 1) in 39.5% of the subjects.</p><p><strong>Conclusions: </strong>The burden and impacts of these conditions are considerable. Thus, the government needs to devise programmes and policies to limit the effects of RMDs in such communities.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 6","pages":"366-375"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/3b/RU-60-156144.PMC9847106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10581041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. A型肉毒毒素注射治疗系统性硬化症患者雷诺现象及指溃疡的疗效观察。
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 DOI: 10.5114/reum.2022.120757
Mohammad Hassan Jokar, Bita Baghbani, Kiarash Roustai Geraylow, Jaleh Shariati, Hassan Mehrad-Majd, Zahra Mirfeizi, Kamila Hashemzadeh

Introduction: Systemic sclerosis (SSc) is an autoimmune, connective tissue disorder of unknown etiology which causes vasculopathy and fibrosis. Raynaud's phenomenon (RP) is a common complication of SSc, which leads to ischemia and gangrenes. Treatment of RP is a clinical problem and often remains insufficient.This study aimed to evaluate the therapeutic efficacy of local injections of botulinum toxin type A (BTX-A) in improving the symptoms of Raynaud's phenomenon (RP) secondary to scleroderma.

Material and methods: This parallel single-blinded, placebo-controlled clinical trial enrolled 29 patients with scleroderma. Participants received BTX-A in the first, 2nd, 3rd, and 4th dorsal web spaces and the base of the thumb and small finger of the non-dominant hand and 2.5 ml of sterile normal saline in the opposite hand. Pre-injection measurements and post-injection follow-up evaluations at months 1 and 4 were performed. We compared the outcomes using the paired Student's t-test.

Results: The change in pain severity between pre-injection and month 1 follow-up was significantly larger in the BTX-A group (p-value = 0.04). Between pre-injection and month 1 and month 4, the changes in the Raynaud's condition score (RCS) (p-value = 0.02, 0.004, respectively) and the number of Raynaud's attacks (p-value = 0.006, 0.001, respectively) were significantly greater in the BTX-A group. No significant difference was found in terms of paresthesia, skin thickening, upper extremity function, ulcer diameter, number of ulcers, or Raynaud's attack duration between the two groups (p-value > 0.05). In time, the decrease in pain severity, paresthesia, RCS, number of ulcers, and ulcer diameter, and the increase in upper extremity function were significantly greater in the BTX-A group as compared to the placebo group (p < 0.05).

Conclusions: Our study showed that local injection of BTX-A is safe and has beneficial therapeutic effects on RP and RP-related digital ulcers in SSc patients.

系统性硬化症(SSc)是一种病因不明的自身免疫性结缔组织疾病,可引起血管病变和纤维化。雷诺现象(RP)是SSc的常见并发症,可导致缺血和坏疽。RP的治疗是一个临床问题,往往仍然不足。本研究旨在评价局部注射A型肉毒毒素(BTX-A)改善硬皮病继发雷诺现象(RP)症状的疗效。材料和方法:这项平行、单盲、安慰剂对照的临床试验纳入了29例硬皮病患者。参与者在非惯用手的第一、第二、第三和第四背蹼间隙以及拇指和小指基部接受BTX-A,另一只手接受2.5 ml无菌生理盐水。注射前测量和注射后随访评估在第1和4个月。我们使用配对学生t检验比较结果。结果:BTX-A组患者疼痛程度较注射前和随访1个月变化明显较大(p值= 0.04)。注射前与第1个月、第4个月相比,BTX-A组患者的雷诺病情评分(RCS) (p值分别为0.02、0.004)和雷诺发作次数(p值分别为0.006、0.001)的变化均显著高于对照组。两组在感觉异常、皮肤增厚、上肢功能、溃疡直径、溃疡数、雷诺发作时间等方面差异均无统计学意义(p值> 0.05)。BTX-A组疼痛严重程度、感觉异常、RCS、溃疡数量、溃疡直径的降低以及上肢功能的增加均显著高于安慰剂组(p < 0.05)。结论:我们的研究表明,局部注射BTX-A对SSc患者RP及RP相关指溃疡的治疗是安全的,并且有有益的效果。
{"title":"Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.","authors":"Mohammad Hassan Jokar,&nbsp;Bita Baghbani,&nbsp;Kiarash Roustai Geraylow,&nbsp;Jaleh Shariati,&nbsp;Hassan Mehrad-Majd,&nbsp;Zahra Mirfeizi,&nbsp;Kamila Hashemzadeh","doi":"10.5114/reum.2022.120757","DOIUrl":"https://doi.org/10.5114/reum.2022.120757","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic sclerosis (SSc) is an autoimmune, connective tissue disorder of unknown etiology which causes vasculopathy and fibrosis. Raynaud's phenomenon (RP) is a common complication of SSc, which leads to ischemia and gangrenes. Treatment of RP is a clinical problem and often remains insufficient.This study aimed to evaluate the therapeutic efficacy of local injections of botulinum toxin type A (BTX-A) in improving the symptoms of Raynaud's phenomenon (RP) secondary to scleroderma.</p><p><strong>Material and methods: </strong>This parallel single-blinded, placebo-controlled clinical trial enrolled 29 patients with scleroderma. Participants received BTX-A in the first, 2<sup>nd</sup>, 3<sup>rd</sup>, and 4<sup>th</sup> dorsal web spaces and the base of the thumb and small finger of the non-dominant hand and 2.5 ml of sterile normal saline in the opposite hand. Pre-injection measurements and post-injection follow-up evaluations at months 1 and 4 were performed. We compared the outcomes using the paired Student's <i>t</i>-test.</p><p><strong>Results: </strong>The change in pain severity between pre-injection and month 1 follow-up was significantly larger in the BTX-A group (<i>p</i>-value = 0.04). Between pre-injection and month 1 and month 4, the changes in the Raynaud's condition score (RCS) (<i>p</i>-value = 0.02, 0.004, respectively) and the number of Raynaud's attacks (<i>p</i>-value = 0.006, 0.001, respectively) were significantly greater in the BTX-A group. No significant difference was found in terms of paresthesia, skin thickening, upper extremity function, ulcer diameter, number of ulcers, or Raynaud's attack duration between the two groups (<i>p</i>-value > 0.05). In time, the decrease in pain severity, paresthesia, RCS, number of ulcers, and ulcer diameter, and the increase in upper extremity function were significantly greater in the BTX-A group as compared to the placebo group (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Our study showed that local injection of BTX-A is safe and has beneficial therapeutic effects on RP and RP-related digital ulcers in SSc patients.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 6","pages":"392-398"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/ec/RU-60-152148.PMC9847105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10571848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical presentation, radiological findings and treatment options in Hughes-Stovin syndrome. Hughes-Stovin综合征的临床表现、影像学表现及治疗选择。
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 Epub Date: 2022-05-18 DOI: 10.5114/reum.2022.115666
Melek Kechida, Syrine Daadaa, Walid Jomaa

Hughes-Stovin syndrome is a rare disease characterized by thrombophlebitis associated with arterial or bronchial aneurysms. Even though it was described first in 1911, it is scarcely reported in the literature. Hughes-Stovin syndrome diagnosis is based on clinical manifestations as well as radiological findings. There are no validated criteria or specific laboratory findings to confirm the diagnosis. Computed tomography pulmonary angiography remains the gold standard for the diagnosis and follow-up of radiological findings, as they were recently described in a critical analysis of the largest cohort in the literature. The aim of this review is to draw attention to this rare but potentially fatal disease and to discuss its therapeutic options.

休斯-斯托文综合征是一种罕见的疾病,以动脉或支气管动脉瘤相关的血栓性静脉炎为特征。尽管它在1911年首次被描述,但在文献中几乎没有报道。休斯-斯托文综合征的诊断是基于临床表现和放射学结果。没有有效的标准或具体的实验室结果来确认诊断。计算机断层肺血管造影仍然是诊断和随访影像学表现的金标准,正如最近在文献中最大队列的关键分析中所描述的那样。这篇综述的目的是引起人们对这种罕见但可能致命的疾病的关注,并讨论其治疗选择。
{"title":"Clinical presentation, radiological findings and treatment options in Hughes-Stovin syndrome.","authors":"Melek Kechida,&nbsp;Syrine Daadaa,&nbsp;Walid Jomaa","doi":"10.5114/reum.2022.115666","DOIUrl":"https://doi.org/10.5114/reum.2022.115666","url":null,"abstract":"<p><p>Hughes-Stovin syndrome is a rare disease characterized by thrombophlebitis associated with arterial or bronchial aneurysms. Even though it was described first in 1911, it is scarcely reported in the literature. Hughes-Stovin syndrome diagnosis is based on clinical manifestations as well as radiological findings. There are no validated criteria or specific laboratory findings to confirm the diagnosis. Computed tomography pulmonary angiography remains the gold standard for the diagnosis and follow-up of radiological findings, as they were recently described in a critical analysis of the largest cohort in the literature. The aim of this review is to draw attention to this rare but potentially fatal disease and to discuss its therapeutic options.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 2","pages":"148-152"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/05/RU-60-46890.PMC9238307.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The relationship between platelet distribution width and disease activity in patients with polymyositis. 多发性肌炎患者血小板分布宽度与疾病活动性的关系。
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 Epub Date: 2022-11-04 DOI: 10.5114/reum.2022.120760
Gokhan Sargin, Ceren Demir, Songül Cildag, Taskin Senturk

Introduction: Muscle enzymes are an indicator of ongoing muscle damage and disease activity in patients with idiopathic inflammatory myopathy. Although platelet-related parameters have been shown to be useful as markers of disease activity in autoimmune diseases, the relationship between platelet distribution width (PDW) and disease activity has not been previously studied in polymyositis. We aimed to determine the relationship between PDW and disease activity in patients with polymyositis.

Material and methods: Twenty-seven patients with polymyositis and thirty healthy controls were included in the study. Disease activity was evaluated using the myositis disease activity assessment Visual Analogue Scale (MYOACT) and the Myositis Intention to Treat Index (MITAX). The relationship between PDW and disease activity was evaluated using Pearson's or Spearman's correlation and reliability was assessed using correlation coefficients.

Results: The mean platelet volume (MPV) and plateletcrit (PCT) were significantly higher and PDW was significantly lower in patients with polymyositis compared to the control group. The mean PDW levels were lower in patients with constitutional symptoms and arthralgia/arthritis (p < 0.005). Although PDW levels were lower in patients with mechanical hand, lung involvement, or dysphagia compared to patients without, there was no statistically significant difference between them. Platelet distribution width was found to be negatively correlated with disease activity.

Conclusions: We found that PDW was negatively correlated with MYOACT and MITAX, widely used tools in assessing the disease activity of polymyositis. Based on this, PDW may be utilized as a non-invasive potential index to assess disease activity in patients with polymyositis.

肌肉酶是特发性炎性肌病患者持续肌肉损伤和疾病活动的指标。尽管血小板相关参数已被证明可作为自身免疫性疾病疾病活动性的标志物,但在多发性肌炎中,血小板分布宽度(PDW)与疾病活动性之间的关系尚未被研究。我们的目的是确定PDW与多肌炎患者疾病活动性之间的关系。材料与方法:选取27例多发性肌炎患者和30例健康对照者。使用肌炎疾病活动性评估视觉模拟量表(MYOACT)和肌炎治疗意向指数(MITAX)评估疾病活动性。PDW与疾病活动度的关系采用Pearson’s或Spearman’s相关评估,可靠性采用相关系数评估。结果:与对照组相比,多肌炎患者血小板体积(MPV)和血小板电积(PCT)显著增高,血小板电积(PDW)显著降低。有体质症状和关节痛/关节炎的患者平均PDW水平较低(p < 0.005)。尽管与无机械手、肺部受累或吞咽困难的患者相比,有机械手、肺部受累或吞咽困难的患者PDW水平较低,但两者之间没有统计学差异。血小板分布宽度与疾病活动性呈负相关。结论:我们发现PDW与MYOACT和MITAX呈负相关,MYOACT和MITAX是广泛用于评估多发性肌炎疾病活动性的工具。基于此,PDW可作为评估多发性肌炎患者疾病活动性的非侵入性电位指标。
{"title":"The relationship between platelet distribution width and disease activity in patients with polymyositis.","authors":"Gokhan Sargin,&nbsp;Ceren Demir,&nbsp;Songül Cildag,&nbsp;Taskin Senturk","doi":"10.5114/reum.2022.120760","DOIUrl":"https://doi.org/10.5114/reum.2022.120760","url":null,"abstract":"<p><strong>Introduction: </strong>Muscle enzymes are an indicator of ongoing muscle damage and disease activity in patients with idiopathic inflammatory myopathy. Although platelet-related parameters have been shown to be useful as markers of disease activity in autoimmune diseases, the relationship between platelet distribution width (PDW) and disease activity has not been previously studied in polymyositis. We aimed to determine the relationship between PDW and disease activity in patients with polymyositis.</p><p><strong>Material and methods: </strong>Twenty-seven patients with polymyositis and thirty healthy controls were included in the study. Disease activity was evaluated using the myositis disease activity assessment Visual Analogue Scale (MYOACT) and the Myositis Intention to Treat Index (MITAX). The relationship between PDW and disease activity was evaluated using Pearson's or Spearman's correlation and reliability was assessed using correlation coefficients.</p><p><strong>Results: </strong>The mean platelet volume (MPV) and plateletcrit (PCT) were significantly higher and PDW was significantly lower in patients with polymyositis compared to the control group. The mean PDW levels were lower in patients with constitutional symptoms and arthralgia/arthritis (<i>p</i> < 0.005). Although PDW levels were lower in patients with mechanical hand, lung involvement, or dysphagia compared to patients without, there was no statistically significant difference between them. Platelet distribution width was found to be negatively correlated with disease activity.</p><p><strong>Conclusions: </strong>We found that PDW was negatively correlated with MYOACT and MITAX, widely used tools in assessing the disease activity of polymyositis. Based on this, PDW may be utilized as a non-invasive potential index to assess disease activity in patients with polymyositis.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 5","pages":"351-356"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/ba/RU-60-48076.PMC9661407.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of intra-sacroiliac joint methylprednisolone injection in the recovery of patients with spondyloarthropathy: a randomized controlled trial. 骶髂关节内注射甲基强的松龙对脊椎关节病患者康复的影响:一项随机对照试验。
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 Epub Date: 2022-11-04 DOI: 10.5114/reum.2022.120285
Elham Rajaei, Khaled Bavieh, Karim Mowla, Ali Ghorbani, Nooshin Movaffagh

Introduction: Spondyloarthropathies are a group of chronic inflammatory diseases with specific clinical symptoms in rheumatic diseases. These patients suffer from pain in the joints. Physicians have tried several ways to decrease the pain in these patients. This study aimed to evaluate the effect of intra-sacroiliac joint methylprednisolone injection under the guidance of ultrasonography in spondyloarthropathy patients.

Material and methods: In this randomized control trial we studied 60 patients with spondyloarthropathy (30 patients in the intervention group and 30 patients in the control group) from January 2020 to December 2020. The intervention group patients received 40 mg of intra-sacroiliac joint (SIJ) methylprednisolone injection at the beginning in addition to treatment with nonsteroidal anti-inflammatory drugs (inflammatory dose) and sulfasalazine (2 to 3 g/day). Patients' pain intensity and symptoms were assessed in the 2nd, 4th, 6th, and 8th weeks after glucocorticosteroid injection. Quantitative factors were compared by independent Student's t-test. Data analysis was performed using SPSS version 22.0 software. A p-value < 0.005 was considered significant.

Results: There were no statistically significant differences in Visual Analogue Scale (VAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) criteria and finger-to-floor (FTF) levels in the intervention and control groups. There were significant differences in VAS and BASDAI criteria and FTF levels 2 weeks after the injection, and this difference remained the same until the end of the 8th week. The p-value was significant (p-value < 0.0001).

Conclusions: The sacroiliac joint methylprednisolone injection approach with ultrasound guidance seems to be effective in pain relief and function, and patient satisfaction scores. Additionally using the guidance of ultrasonography in this approach is without the risk of radiation exposure.

颈椎病是风湿病中一组具有特定临床症状的慢性炎症性疾病。这些病人饱受关节疼痛之苦。医生们已经尝试了几种方法来减轻这些病人的痛苦。本研究旨在评价超声引导下骶髂关节内注射甲强的松龙治疗腰椎关节病的疗效。材料与方法:在这项随机对照试验中,我们研究了2020年1月至2020年12月60例脊椎关节病患者(干预组30例,对照组30例)。干预组患者在开始时给予骶髂关节内(SIJ)甲基强的松龙注射液40 mg,同时给予非甾体类抗炎药(炎症剂量)和柳氮磺胺吡啶(2 ~ 3g /天)治疗。分别于注射糖皮质激素后第2、4、6、8周评估患者疼痛强度和症状。定量因素比较采用独立学生t检验。数据分析采用SPSS 22.0版软件。p值< 0.005为显著性。结果:干预组和对照组在视觉模拟量表(VAS)、Bath强直性脊柱炎疾病活动指数(BASDAI)标准和指对地(FTF)水平上无统计学差异。注射后2周,两组VAS、BASDAI标准及FTF水平均有显著差异,且这种差异一直保持到第8周结束。p值显著(p值< 0.0001)。结论:超声引导下骶髂关节注射甲强的松龙入路在疼痛缓解、功能改善及患者满意度评分方面均有较好的效果。此外,在这种方法中使用超声引导是没有辐射暴露的风险。
{"title":"The impact of intra-sacroiliac joint methylprednisolone injection in the recovery of patients with spondyloarthropathy: a randomized controlled trial.","authors":"Elham Rajaei,&nbsp;Khaled Bavieh,&nbsp;Karim Mowla,&nbsp;Ali Ghorbani,&nbsp;Nooshin Movaffagh","doi":"10.5114/reum.2022.120285","DOIUrl":"https://doi.org/10.5114/reum.2022.120285","url":null,"abstract":"<p><strong>Introduction: </strong>Spondyloarthropathies are a group of chronic inflammatory diseases with specific clinical symptoms in rheumatic diseases. These patients suffer from pain in the joints. Physicians have tried several ways to decrease the pain in these patients. This study aimed to evaluate the effect of intra-sacroiliac joint methylprednisolone injection under the guidance of ultrasonography in spondyloarthropathy patients.</p><p><strong>Material and methods: </strong>In this randomized control trial we studied 60 patients with spondyloarthropathy (30 patients in the intervention group and 30 patients in the control group) from January 2020 to December 2020. The intervention group patients received 40 mg of intra-sacroiliac joint (SIJ) methylprednisolone injection at the beginning in addition to treatment with nonsteroidal anti-inflammatory drugs (inflammatory dose) and sulfasalazine (2 to 3 g/day). Patients' pain intensity and symptoms were assessed in the 2<sup>nd</sup>, 4<sup>th</sup>, 6<sup>th</sup>, and 8<sup>th</sup> weeks after glucocorticosteroid injection. Quantitative factors were compared by independent Student's <i>t</i>-test. Data analysis was performed using SPSS version 22.0 software. A <i>p</i>-value < 0.005 was considered significant.</p><p><strong>Results: </strong>There were no statistically significant differences in Visual Analogue Scale (VAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) criteria and finger-to-floor (FTF) levels in the intervention and control groups. There were significant differences in VAS and BASDAI criteria and FTF levels 2 weeks after the injection, and this difference remained the same until the end of the 8<sup>th</sup> week. The <i>p</i>-value was significant (<i>p</i>-value < 0.0001).</p><p><strong>Conclusions: </strong>The sacroiliac joint methylprednisolone injection approach with ultrasound guidance seems to be effective in pain relief and function, and patient satisfaction scores. Additionally using the guidance of ultrasonography in this approach is without the risk of radiation exposure.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 5","pages":"332-339"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/d1/RU-60-48004.PMC9661409.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Crowdfunding campaigns for the needs of people with rheumatic diseases living in Poland: a retrospective study. 满足波兰风湿病患者需求的众筹活动:一项回顾性研究。
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 Epub Date: 2022-11-04 DOI: 10.5114/reum.2022.120759
Mikołaj Kamiński, Aleksandra Borys, Paweł Hrycaj

Introduction: Patients with rheumatic diseases may require costly treatment and continuous rehabilitation, which Internet collections may finance. We aimed to characterize medical crowdfunding campaigns for the needs of Polish people with rheumatic diseases.

Material and methods: We utilized data from the largest medical crowdfunding platform in Poland, Siepomaga.pl. All collections in the years 2009-2017 for the needs of people with rheumatic diseases were identified.

Results: Twenty-three of 2,656 collections were included (0.9%). Sixty-five and two percent of campaigns collected the financial target. The median amount of collected funds was 3,369 euros. Ten collections concerned conservative treatments (drug and/or rehabilitation), seven financed surgery, five supported the acquisition of medical equipment or its repair, and one aimed at facilitating a diagnostic consultation with a foreign specialist.

Conclusions: Polish patients with rheumatic diseases collect funds via medical crowdfunding, mostly for needs not covered by public healthcare or to obtain better health services in the private sector.

导言:风湿病患者可能需要昂贵的治疗和持续的康复,互联网收集可以资助。我们的目标是描述波兰风湿病患者需要的医疗众筹活动。材料和方法:我们利用了波兰最大的医疗众筹平台Siepomaga.pl的数据。确定了2009-2017年风湿病患者需要的所有收藏。结果:2656份标本中纳入23份(0.9%)。65%的竞选活动达到了财政目标。筹集资金的中位数为3369欧元。10笔捐款涉及保守治疗(药物和/或康复),7笔捐款资助外科手术,5笔捐款支持购置或维修医疗设备,1笔捐款旨在便利与外国专家进行诊断咨询。结论:波兰风湿病患者通过医疗众筹筹集资金,主要用于公共医疗保健未涵盖的需求或在私营部门获得更好的卫生服务。
{"title":"Crowdfunding campaigns for the needs of people with rheumatic diseases living in Poland: a retrospective study.","authors":"Mikołaj Kamiński,&nbsp;Aleksandra Borys,&nbsp;Paweł Hrycaj","doi":"10.5114/reum.2022.120759","DOIUrl":"https://doi.org/10.5114/reum.2022.120759","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with rheumatic diseases may require costly treatment and continuous rehabilitation, which Internet collections may finance. We aimed to characterize medical crowdfunding campaigns for the needs of Polish people with rheumatic diseases.</p><p><strong>Material and methods: </strong>We utilized data from the largest medical crowdfunding platform in Poland, Siepomaga.pl. All collections in the years 2009-2017 for the needs of people with rheumatic diseases were identified.</p><p><strong>Results: </strong>Twenty-three of 2,656 collections were included (0.9%). Sixty-five and two percent of campaigns collected the financial target. The median amount of collected funds was 3,369 euros. Ten collections concerned conservative treatments (drug and/or rehabilitation), seven financed surgery, five supported the acquisition of medical equipment or its repair, and one aimed at facilitating a diagnostic consultation with a foreign specialist.</p><p><strong>Conclusions: </strong>Polish patients with rheumatic diseases collect funds via medical crowdfunding, mostly for needs not covered by public healthcare or to obtain better health services in the private sector.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 5","pages":"347-350"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/6e/RU-60-48075.PMC9661406.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study. 用生物制剂和 JAK-STAT 抑制剂治疗严重类风湿性关节炎患者的比较。一项观察性研究。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2022-01-01 Epub Date: 2022-05-18 DOI: 10.5114/reum.2022.115987
Małgorzata Wisłowska

Introduction: Treatment of severe rheumatoid arthritis (RA) is currently based either on biological agents or Janus kinase/signal transducer and activator of transcription inhibitors, most often in combination with methotrexate (MTX).

Aim of the study: The aim of the study was to compare the effectiveness and side effects of bio- logic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) DMARDs treatment.

Material and methods: The analysis included 108 RA patients with active disease treated with MTX 25 mg per week. Eighty patients (group I) were treated with bDMARDs and 28 patients (group II) with JAK-STAT inhibitors. The duration of morning stiffness, pain on Visual Analogue Scale (VAS), 28-joints Disease Activity Score (DAS28) and Simplified Disease Activity Score (SDAI) were assessed. Classical radiographic images of patients' hands and feet using the Larsen and Dale's criteria were evaluated. The effects of treatment with bDMARDs and tsDMARDs were analyzed.

Results: All studied patients presented at least Larsen and Dale's stage 3 of X-ray changes typical for RA. There were no statistically significant differences in disease duration, ESR, CRP, DAS28 and SDAI values between studied groups. Patients from group II previously used higher numbers of bDMARDs than group I treated with bDMARDs. Low disease activity after treatment was achieved by all patients; therefore patients from group II (treated with tsDMARDs) achieved lower values of patients' global assessment on VAS.

Conclusions: The results of the present observational study indicated that treatment with JAK inhibitors is very promising. These drugs are not inferior in effectiveness to bDMARDs. It is important to monitor patients for thromboembolic events before and during JAK treatment.

导言:目前,治疗严重类风湿性关节炎(RA)的药物主要是生物制剂或Janus激酶/信号转导和转录激活剂抑制剂,最常见的是与甲氨蝶呤(MTX)联合使用:研究旨在比较生物逻辑疾病修饰抗风湿药(bDMARDs)和靶向合成(ts)DMARDs治疗的有效性和副作用:分析对象包括108名患有活动性疾病的RA患者,他们每周接受25毫克MTX治疗。80名患者(I组)接受了bDMARDs治疗,28名患者(II组)接受了JAK-STAT抑制剂治疗。对晨僵持续时间、视觉模拟量表(VAS)显示的疼痛、28关节疾病活动度评分(DAS28)和简化疾病活动度评分(SDAI)进行了评估。采用 Larsen 和 Dale 标准对患者手脚的经典放射影像进行了评估。分析了使用bDMARDs和tsDMARDs治疗的效果:结果:所有研究对象都至少达到了拉森和戴尔标准的第 3 阶段,出现了典型的 RA X 射线变化。研究组之间在病程、血沉、CRP、DAS28 和 SDAI 值方面没有明显的统计学差异。II 组患者之前使用的 bDMARDs 药物数量高于接受 bDMARDs 治疗的 I 组患者。所有患者在治疗后均有较低的疾病活动度;因此,II 组患者(使用 tsDMARDs 治疗)在 VAS 上获得的患者总体评估值较低:本观察性研究的结果表明,JAK 抑制剂的治疗前景非常广阔。结论:本观察性研究结果表明,JAK 抑制剂的治疗前景非常广阔,其疗效并不比 bDMARDs 差。在JAK治疗前和治疗期间监测患者血栓栓塞事件非常重要。
{"title":"Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study.","authors":"Małgorzata Wisłowska","doi":"10.5114/reum.2022.115987","DOIUrl":"10.5114/reum.2022.115987","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of severe rheumatoid arthritis (RA) is currently based either on biological agents or Janus kinase/signal transducer and activator of transcription inhibitors, most often in combination with methotrexate (MTX).</p><p><strong>Aim of the study: </strong>The aim of the study was to compare the effectiveness and side effects of bio- logic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) DMARDs treatment.</p><p><strong>Material and methods: </strong>The analysis included 108 RA patients with active disease treated with MTX 25 mg per week. Eighty patients (group I) were treated with bDMARDs and 28 patients (group II) with JAK-STAT inhibitors. The duration of morning stiffness, pain on Visual Analogue Scale (VAS), 28-joints Disease Activity Score (DAS28) and Simplified Disease Activity Score (SDAI) were assessed. Classical radiographic images of patients' hands and feet using the Larsen and Dale's criteria were evaluated. The effects of treatment with bDMARDs and tsDMARDs were analyzed.</p><p><strong>Results: </strong>All studied patients presented at least Larsen and Dale's stage 3 of X-ray changes typical for RA. There were no statistically significant differences in disease duration, ESR, CRP, DAS28 and SDAI values between studied groups. Patients from group II previously used higher numbers of bDMARDs than group I treated with bDMARDs. Low disease activity after treatment was achieved by all patients; therefore patients from group II (treated with tsDMARDs) achieved lower values of patients' global assessment on VAS.</p><p><strong>Conclusions: </strong>The results of the present observational study indicated that treatment with JAK inhibitors is very promising. These drugs are not inferior in effectiveness to bDMARDs. It is important to monitor patients for thromboembolic events before and during JAK treatment.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 2","pages":"81-91"},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/35/RU-60-46973.PMC9238315.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40556411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paraneoplastic arthritides: an up-to-date case-based systematic review. 副肿瘤关节炎:最新的基于病例的系统回顾。
Q3 RHEUMATOLOGY Pub Date : 2022-01-01 DOI: 10.5114/reum.2022.123672
Suhel Gabriele Al Khayyat, Edoardo Conticini, Paolo Falsetti, Stefano Gentileschi, Antonio Vitale, Salvatore Massimo Stella, Miriana D'Alessandro, Elena Bargagli, Luca Cantarini, Bruno Frediani

Among the rheumatic diseases whose symptoms are more often associated with the possibility of cancer and other malignancies are systemic sclerosis, dermatomyositis and rheumatic polymyalgia. However, a differential diagnosis should be performed in each case of non-typical rheumatic disease and/or other neoplastic disease risk factors. The article's aim was based on a literature review of this subject and presentation own a case description and discussion about arthritis as a paraneoplastic syndrome. The conclusions of our analysis were as follows: more often paraneoplastic arthritis occurs in men, in ages higher than 50 years old, in patients who poorly respond to treatment of arthritis with polyarticular symmetrical involvement of the limbs, seronegative type of inflammatory joint disease. In this group of patients, complete remission after treatment of the primary tumor and recurrence of the symptoms in the presence of metastasis was observed.

在风湿病中,其症状更常与癌症和其他恶性肿瘤的可能性相关的有系统性硬化症、皮肌炎和风湿性多肌痛。然而,对于非典型风湿病和/或其他肿瘤疾病的危险因素,应进行鉴别诊断。这篇文章的目的是基于对这一主题的文献回顾,并介绍了一个关于关节炎作为副肿瘤综合征的病例描述和讨论。我们分析的结论如下:副肿瘤性关节炎更常发生在男性,年龄大于50岁,在对多关节对称受累的四肢关节炎治疗反应不佳的患者中,血清阴性型炎症性关节疾病。在这组患者中,观察到原发肿瘤治疗后完全缓解,在存在转移的情况下症状复发。
{"title":"Paraneoplastic arthritides: an up-to-date case-based systematic review.","authors":"Suhel Gabriele Al Khayyat,&nbsp;Edoardo Conticini,&nbsp;Paolo Falsetti,&nbsp;Stefano Gentileschi,&nbsp;Antonio Vitale,&nbsp;Salvatore Massimo Stella,&nbsp;Miriana D'Alessandro,&nbsp;Elena Bargagli,&nbsp;Luca Cantarini,&nbsp;Bruno Frediani","doi":"10.5114/reum.2022.123672","DOIUrl":"https://doi.org/10.5114/reum.2022.123672","url":null,"abstract":"<p><p>Among the rheumatic diseases whose symptoms are more often associated with the possibility of cancer and other malignancies are systemic sclerosis, dermatomyositis and rheumatic polymyalgia. However, a differential diagnosis should be performed in each case of non-typical rheumatic disease and/or other neoplastic disease risk factors. The article's aim was based on a literature review of this subject and presentation own a case description and discussion about arthritis as a paraneoplastic syndrome. The conclusions of our analysis were as follows: more often paraneoplastic arthritis occurs in men, in ages higher than 50 years old, in patients who poorly respond to treatment of arthritis with polyarticular symmetrical involvement of the limbs, seronegative type of inflammatory joint disease. In this group of patients, complete remission after treatment of the primary tumor and recurrence of the symptoms in the presence of metastasis was observed.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 6","pages":"422-436"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/63/RU-60-156257.PMC9847110.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10581045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Reumatologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1